Parkinson Disease, Parkinsonian Disorders
Conditions
Brief summary
The aim of this study is to determine whether a significant reduction in the total level of alpha-synuclein and significant increase in the oligomeric form of alpha-synuclein and therefore the ratio oligomeric:total alpha-synuclein occurs in patients with Parkinson disease compared to patients with drug-induced parkinsonian syndrome.
Interventions
DIAGNOSTIC_TESTLevel of alpha-synuclein
Test of levels of total and ratio total:oligomeric in saliva
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Inclusion criteria
* The patient must have given their free and informed consent and signed the consent form * The patient must be insured or the beneficiary of an insurance policy * The patient is less than 55 years old * For patients with acquired parkinsonian syndrome (UKPDSBB criteria) currently at HOEHN and YAHR stage ≤3: * For patients recruited via a psychiatrist: after anti-dopamine treatment * For patients recruited via a neurologist: having a recent diagnosis (≤2 years) of Parkinson disease
Exclusion criteria
* The subject is participating in another study * The subject is in an exclusion period determined by a previous study * The patients is under judicial protection * The subject or their representative refused to sign the consent form * It proves impossible to give the subject or their representative clear information. * Patients with atypical degenerative parkinsonian syndrome * Patients with vascular, post-traumatic, metabolic, toxic or genetic parkinsonian syndrome * Appearance of parkinsonian syndrome prior to treatment with anti-dopamine * Injection of botulinum toxin into the salivary glands * Contra-indication on DAT-scan (unbalanced dysthyroidism, allergy, treatment with bupropion or amphetaminergics) * Poor oral health (polyposis, gingivostomatitis) observed during the odontologist visit * Patients not taking anti-psychotics with parkinsonian syndrome and normal DAT-scan
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compare saliva level of oligomeric alpha-synuclein between two groups of patients wth classical parkinsonian: patients with idiopathic Parkinson disease and patients with a acquired parkinsonian syndrome from anti-dopamine treatment. | Day 0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compare levels of total alpha-synuclein and the ratio of oligomeric alpha-synuclein:total alpha-synuclein between the two groups | Day 0 | — |
| Perform the first estimation of discriminatory capacity of saliva levels of total oligomeric alpha-synuclein and the ratio of oligomeric alpha-synuclein:total alpha-synuclein for diagnostic differentiation between two groups | Day 0 | — |
| Creation of a biobank with remaining samples | Day 0 | saliva samples |
| UPDRS II-III-IV score | Day 0 | — |
| UDysRs score | Day 0 | — |
| Perform the first estimation of discriminatory capacity of saliva levels of oligomeric alpha-synuclein for diagnostic differentiation between idiopathic Parkinson disease and anti-dopamine induced acquired parkinsonian syndrome. | Day 0 | — |
| akathisia | Day 0 | — |
| questionnaire on non-motor symptoms in Parkinson disease | Day 0 | PD-NMS |
| neuro-psychological evaluation | Day 0 | BREF+MOCO score |
| GDS score | Day 0 | — |
| interogation to determine extent of motor and non-motor clinical markers to differentiate the two groups | Day 0 | — |
| character of parkinsonian syndrome | Day 0 | symmetrical or asymmetrical |
Countries
France
Outcome results
None listed